D46.73 Myelodysplastic syndrome with 5q deletion

Name of the Condition

• Myelodysplastic syndrome with 5q deletion

Summary

Myelodysplastic syndrome with 5q deletion is a subtype of myelodysplastic syndrome (MDS) characterized by low blood cell counts (cytopenias) and a specific chromosomal abnormality involving a deletion on the long arm of chromosome 5 (5q deletion). This condition is marked by ineffective blood cell production in the bone marrow, leading to symptoms such as anemia, fatigue, and increased infection risk. It may progress to acute myeloid leukemia (AML) in some cases.

Causes

The exact cause of myelodysplastic syndrome with 5q deletion is often unknown. It may involve genetic mutations that disrupt normal blood cell production, including the 5q deletion itself. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify cytopenias, followed by a bone marrow biopsy to assess cell dysplasia. Cytogenetic analysis is performed to detect the 5q deletion, and additional tests may evaluate iron levels or rule out other causes of cytopenias.

Treatment Options

Treatment depends on the severity of symptoms and risk of progression. Options may include blood transfusions, growth factors to stimulate blood cell production, and targeted therapies (e.g., lenalidomide for low-risk disease). In some cases, stem cell transplantation may be considered.

Prognosis and Follow-Up

Prognosis varies based on the severity of cytopenias and other risk factors. Regular monitoring of blood counts and bone marrow status is essential to detect progression to AML. Follow-up care focuses on managing symptoms and adjusting treatment as needed.

Complications

• Increased risk of infections due to low white blood cell counts
• Bleeding or bruising from low platelet counts
• Progression to acute myeloid leukemia (AML)
• Fatigue and reduced quality of life from anemia

Lifestyle & Prevention

• Avoid exposure to chemicals like benzene
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with healthcare providers for monitoring

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. These symptoms may indicate worsening cytopenias or disease progression.

Tips for Medical Coders

Document the presence of the 5q deletion and any associated cytopenias (e.g., anemia, thrombocytopenia) to support the diagnosis. Ensure coding aligns with clinical documentation, as the 5q deletion is a key diagnostic criterion for this subtype.